Literature DB >> 33754933

Targeting Fc effector function in vaccine design.

Simone I Richardson1,2, Penny L Moore1,2,3.   

Abstract

INTRODUCTION: Antibodies mediate pathogen neutralization in addition to several cytotoxic Fc functions through engaging cellular receptors and recruiting effector cells. Fc effector functions have been well described in disease control and protection against infectious diseases including HIV, Ebola, malaria, influenza and tuberculosis, making them attractive targets for vaccine design. AREAS COVERED: We briefly summarize the role of Fc effector functions in disease control and protection in viral, bacterial and parasitic infectious diseases. We review Fc effector function in passive immunization and vaccination, and primarily focus on strategies to elicit and modulate these functions as part of a robust vaccine strategy. EXPERT OPINION: Despite their known correlation with vaccine efficacy for several diseases, only recently have seminal studies addressed how these Fc effector functions can be elicited and modulated in vaccination. However, gaps remain in assay standardization and the precise mechanisms of diverse functional assays. Furthermore, there are inherent difficulties in the translation of findings from animal models to humans, given the difference in sequence, expression and function of Fc receptors and Fc portions of antibodies. However, overall it is clear that vaccine development to elicit Fc effector function is an important goal for optimal prevention against infectious disease.

Entities:  

Keywords:  Fc effector function; SARS-CoV-2; infectious disease; passive immunization; vaccination

Year:  2021        PMID: 33754933     DOI: 10.1080/14728222.2021.1907343

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  7 in total

Review 1.  Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.

Authors:  Dhuha H Nawab
Journal:  Hum Vaccin Immunother       Date:  2021-11-29       Impact factor: 3.452

2.  SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.

Authors:  Simone I Richardson; Nelia P Manamela; Boitumelo M Motsoeneng; Haajira Kaldine; Frances Ayres; Zanele Makhado; Mathilda Mennen; Sango Skelem; Noleen Williams; Nancy J Sullivan; John Misasi; Glenda G Gray; Linda-Gail Bekker; Veronica Ueckermann; Theresa M Rossouw; Michael T Boswell; Ntobeko A B Ntusi; Wendy A Burgers; Penny L Moore
Journal:  Cell Rep Med       Date:  2022-01-17

3.  Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.

Authors:  Yucheol Cheong; Minjin Kim; Jina Ahn; Hana Oh; Jongkwan Lim; Wonil Chae; Seung Won Yang; Min Seok Kim; Ji Eun Yu; Sanguine Byun; Yo Han Jang; Baik Lin Seong
Journal:  Front Immunol       Date:  2021-11-12       Impact factor: 7.561

Review 4.  Fc receptors and the diversity of antibody responses to HIV infection and vaccination.

Authors:  Li-Yun Lin; Raphael Carapito; Bin Su; Christiane Moog
Journal:  Genes Immun       Date:  2022-06-10       Impact factor: 4.248

5.  The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia.

Authors:  Chuangqi Wang; Yijia Li; Paulina Kaplonek; Matteo Gentili; Stephanie Fischinger; Kathryn A Bowman; Moshe Sade-Feldman; Kyle R Kays; James Regan; James P Flynn; Marcia B Goldberg; Nir Hacohen; Michael R Filbin; Douglas A Lauffenburger; Galit Alter; Jonathan Z Li
Journal:  mBio       Date:  2022-06-28       Impact factor: 7.786

6.  HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.

Authors:  Simone I Richardson; Frances Ayres; Nelia P Manamela; Brent Oosthuysen; Zanele Makhado; Bronwen E Lambson; Lynn Morris; Penny L Moore
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

Review 7.  Broadly Neutralizing Antibodies for HIV-1 Prevention.

Authors:  Stephen R Walsh; Michael S Seaman
Journal:  Front Immunol       Date:  2021-07-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.